1 Day
Source:
مباشر
_1777294237270_124456903.png&w=64&q=75){kind=small}
China Nod Lifts Lilly
Eli Lilly shares rose 2.8% in premarket trading after China’s drug regulator approved its oral weight-loss drug, orforglipron. The approval strengthens the company’s position against Novo Nordisk: the oral version of Wegovy has not been cleared in China, while Lilly’s drug targets patients who prefer pills to injections in a market where more than 65% of the population is expected to be overweight or obese by 2030.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)